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Abstract
Background: Congestive heart failure (HF) is a chronic, frequent and disabling condition but
with a modifiable course and a large potential for improving. The aim of this project was to develop
a clinical prediction model of biological and non biological factors in patients with first diagnosis of
HF that facilitates the risk-stratification and decision-making process at the point of care.
Methods and Results: Historical cohort analysis of 600 patients attended at three tertiary
hospitals and diagnosed of a first episode of HF according Framingham criteria. There were
followed 1 year. We analyzed sociodemographic, clinical and laboratory data with potential
prognostic value. The modelling process concluded into a logistic regression multivariable
analysis and a predictive rule: PREDICE SCORE. Age, dependency for daily basic activities,
creatinine clearance, sodium levels at admission and systolic dysfunction diagnosis (HF with left
ventricular ejection fraction < 40%) were the selected variables. The model showed a c-statistic
of 0.763. PREDICE Score, has range of 22 points to stratifications of 1-year mortality.
Conclusions: The follow-up of 600 patients hospitalized by a first episode of congestive HF,
allowed us to obtain a predictive 1 year mortality model from the combination of demographic
data, routine biochemistry and easy handling social and functional variables at the point of
care. The variables included were non-invasive, undemanding to collect, and widely available.
It allows for risk stratification and therapeutical targeting and may help in the clinical
decisions process in a sustainable way. (Cardiol J 2012; 19, 6: 578–585)
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Introduction
Heart failure (HF) is a disease known to
progress with high morbidity and mortality [1, 2].
Epidemiological studies have shown that HF pa-
tients suffer a significant deterioration in their qua-
lity of life and progress worse than many types of
cancer [3].
The prognosis for patients diagnosed as hav-
ing HF remains poor. In 2002, risk adjusted 1-year
mortality was 27.5% (95% CI 27.1–27.9), more than
3 times higher than for age and sex matched pa-
tients [1].
However it is a clinical entity with a modifiable
course and with high potential for control and health
status improvement. The management of chronic
diseases has become a need in health systems so
they are already implementing health initiatives and
strategies, which are profitable and sustainable and
aimed at improving patient care [4, 5].
Related to HF it has been demonstrated that
disease management programmes in HF can reduce
mortality and readmission, optimizing medication,
providing education, coordinating care, and facili-
tating self-care as recommended in international
guidelines [6–9].
For patients with HF it is possible to make
a prognostic estimation from parameters that are
easy for the clinician to obtain and transforming
them in a clinical prediction rule at point of care
using exclusively clinical, biochemical, personal and
social parameters acquired from anamnesis and
patient exploration [10].
Most of the predictive models described for
patients with HF are mainly based on constitution-
al aspects: (age [10–12], gender [12], body mass
index [13, 14]), clinical data detected through ex-
ploration [15, 16], biochemical markers [10, 17, 18],
kidney function impairment parameters [10, 19–21],
hyponatremia [17, 22, 23], electrocardiographic al-
terations (QRS prolongation, QRS low voltage, atrial
fibrillation) [24], the findings in the cardiac function
test as echocardiogram (left ventricular ejection
fraction [LVEF] < 45%) [20, 25, 26], left atrial dia-
meter or right ventricle dysfunction, New York
Heart Association  functional classification (NYHA)
[10, 11, 18, 20, 27], alteration of the 6-minute walk
test [28] or associated diseases, such as hyperten-
sion, chronic obstructive pulmonary disease, diabe-
tes or kidney disease [10–12, 18, 21, 22, 29–31].
Many of them are complex to undertake at the
point of care while ignoring something crucial for
the improvement of patient clinical evolution such
as, the patient’s functioning and social support, as
components of prognostic evolution and thus as
therapeutic targets. In fact, social aspects are giv-
en scant consideration in the trials as possible pre-
dictive factors of mortality [32, 33] and rehospita-
lization [34, 35].
Very few studies have evaluated specifically
their impact in cardiovascular mortality [36, 37]. In
spite of this, it is plausible to think that personal
functioning and social support are prognostic fac-
tors, which are usually ignored but which would
have a great potential for action in individuals with
HF and even being incorporated in clinical predic-
tion rules.
So, the main objective of this study was to de-
velop a practical and user-friendly clinical prediction
algorithm of biological and non biological factors in
naïve patients admitted to hospital after a first epi-
sode of chronic HF, PREDICE-score. In order to
facilitate the decision-making process and help in
risk stratification for immediate care and design of
long-term strategies for secondary prevention. The
outcome chosen to test the predictive skills of the
involved factors was mortality at 1 year.
Methods [10, 18]
Study design
This observational, historical cohort study was
conducted at three tertiary care hospitals with large
dependent health districts (over 500.000 inhabi-
tants), the Hospital 12 de Octubre of Madrid (Spain),
the Rocio Hospital of Seville (Spain) and the Valme
Hospital of Seville (Spain).
The study population consisted of patients at
study hospitals that involved emergency admission
with HF (following Framingham criteria) and aged
over 17 years old, between 2003 and 2006, both
years included. Inclusion criteria were: patient
treated at the study center between 01/01/2003 and
31/12/2006, with a primary diagnosis of HF, over
18-year-old, residents in the area of reference of the
study center. Exclusion criteria: those with HF as
a complication after admission. Patients were fol-
lowed up for 1 year from the time of inclusion. In-
vestigators retrospectively acquired all the clinical
information from inpatient medical records and con-
sidered 1 year follow-up information through out-
patient medical records.
The study was approved by the Ethics Com-
mittee of the leader hospital and performed in ac-
cordance with Good Clinical Practices criteria.
Protocol study included patient’s related infor-
mation: demographic data; clinical data, previous
cardiovascular risk factors, previous cardiovascu-
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lar events, previous cardiovascular and non-cardio-
vascular significant diseases; subtype of ischemic
congestive HF, based on Framingham classification;
therapy related data after first-ever ischemic con-
gestive HF episode and findings of ultrasonography,
scintigraphy and coronagraphy; sociodemographic
and psychosocial variables examined: social and
family support [32]: home environment was ana-
lyzed, that is, if the patient lived alone, with family
or at a care home, regardless of the degree of for-
mal support received. Patient’s autonomy: the de-
gree of autonomy of the patient was evaluated and
also the dependence for basic activities [38] and for
instrumental activities [39].
Statistical analysis
Qualitative variables are expressed as absolute
frequencies and percentages. Continuous variables
are described using mean, median, standard devia-
tion and range. Firstly, significant risk factors for
congestive HF mortality were identified using
c2 test in case of qualitative variable. In other cases,
T-Student test or nonparametric Mann-Whitney
test were used depending on variable normality.
Secondly, a multivariate analysis of significant risk
factors of congestive HF identified in the bivariate
analysis, as well as other risk factors that we con-
sidered clinically relevant, was performed using
a logistic regression. Odd ratios (OR) and 95% con-
fidence intervals (CI) were calculated for each risk
factor.
For the validity of the model’s estimations,
Hosmer-Lemeshow test was used and in the same
way, the area under the receiver operating charac-
teristic (ROC) curve was calculated to evaluate the
performance (predictive ability) of the regression
model.
The logistic regression model was converted
to a more user-friendly integer score predicting
an individual’s probability of mortality within
12 months. With each quantitative factor grouped
into categories, an individual score increases by an
integer amount for each level above the lowest cat-
egory. Each integer amount is a rounding of the ex-
act coefficient obtained from the logistic regression
model. A 0 score should mean that a person is at
very low risk and a 22 score should mean that the
individual is at very high risk. This risk score was
based on increasing categories of probability of
death, based on the methodology of risk score func-
tion implemented in the Framingham study [40]. All
the analyses were considered to be significant at
a p-value < 0.05. All statistical analyses were carried
out using STATA/SE 10 software.
Results
Descriptive study by 1-year
mortality groups
The mean age of the patients was 73.5 ± 12.3 ye-
ars and 50.8% were female. There were 98 deaths
amongst the study population (n = 600), which
means an overall mortality rate of 16.3%, with no
statistically significant differences by sex (16.27%
women, 16.39% male; p = 0.968). Table 1 describes
and compares the baseline demographic character-
istics; clinical, social, analytical data and pharmaco-
logical treatment, depending on the outcome ob-
served annually. Comparison was made between
the patients who died and those who did not. Pa-
tients who died the year following the HF diagnostic,
had a creatinine clearance value which was statis-
tically significantly lower, 57.2 ± 32.16 vs. 76.47 ±
± 39, p = 0.000.
The most frequent diagnosed type of HF was
diastolic HF, which affected 74.5% of the study sam-
ple. The presentation of systolic HF was statisti-
cally significantly higher in the deceased group
(36.3%) compared to those who did not die 22.1%
(p = 0.000); 16,5% of patients had ischemic cardio-
pathy, 29.5% had atrial fibrillation and 26.6% had
associated valvulopathies. The outcome observed
at end of 1 year did not differ significantly regard-
less associated cardiovascular diseases.
Taking into account the pharmacological treat-
ment used for HF, in the deceased group, were in-
dicated significantly less ACE inhibitors (42.7% vs.
56.94%; p = 0.01), beta-blockers (19.9% vs.
33.53%; p = 0.008) and oral anticoagulants (23.5%
vs. 35.9%; p = 0.018). There were no differences
between study groups for the rest of the pharma-
cological groups.
The results obtained from the non-biological
variables evaluated are presented in Table 2, where
it is shown that mortality is superior in patients who
were dependent for instrumental and basic activi-
ties without influence of social support.
Predictive 1-year mortality model for
heart failure. The results of independent prognos-
tic factors of 1-year mortality for patients with HF
identified in the multivariable analysis are included
in Table 3. Within the group of biological variables,
the following showed to be independent predictors:
age, creatinine clearance and sodium levels at ad-
mission, systolic dysfunction diagnosis (HF with LVEF
< 40%). Amongst the social variables, the most im-
portant were functional dependence for basic daily
activities. The Figure 1 showed ROC curve of the
predictive 1-year mortality model for HF.
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Table 1. Basal biological characteristics of overall population study and comparison between outco-
mes at 1 year after discharge in patients with heart failure (HF).
Biological characteristic All (n = 600) Death (n = 98) Non death (n = 502) P
Demographics
Age [years] 73.57 ± 12.32 78.06 ± 9.88 72.69 ± 12.57 0.000
Male 295 (49.17%) 48 (48.97%) 247 (49.20)
0.968
Female 305 (50.79%) 50 (51.02%) 255 (50.79%)
Comorbidity
Ischemic cardiopathy 98 (16.33%) 79 (15.74%) 19 (19.39%) 0.371
Atrial fibrillation 177 (29.50%) 27 (27.55%) 150 (29.88%) 0.664
Valvulopathy 160 (26.67%) 32 (32.65%) 128 (25.50%) 0.143
Pathophysiological diagnosis*
Systolic HF 106 (23.93%) 21 (36.84%) 85 (22.02%) 0.034
Diastolic HF 305 (68.85%) 31 (54.39%) 274 (70.98%)
Unknown HF 32 (7.22%) 5 (8.77%) 27 (6.99%)
NYHA scale
Class I. Without limiting 203 (33.83%) 25 (25.50%) 178 (35.50%) 0.144
the habitual physical activity
Class II. Slight limitation 224 (37.33%) 42 (42.90%) 182 (36.30%)
of physical activity routine
Class III. Marked limitation of 136 (22.67%) 27 (27.60%) 109 (21.70%)
physical activity. No dyspnea at rest
Class IV. Dyspnea at rest 37 (6.17%) 4 (4.17%) 33 (6.60%)
Urgency exploration:
DBP [mm Hg] 78.53 ± 18.55 73.71 ± 17.52 79.47 ± 18.62 0.005
SBP [mm Hg] 143.08 ± 31.35 136.71 ± 30.58 144.31 ± 31.38 0.029
Glucemy [mg/dL] 158.75 ± 81.66 171.04 ± 98.55 156.35 ± 77.83 0.166
Total cholesterol [mg/dL] 175.56 ± 43.99 168.12 ± 46.16 176.98 ± 43.48 0.097
Sodium [mEq/L] 138.09 ± 4.60 137.20 ± 5.23 138.26 ± 4.46 0.037
Potasium [mEq/L] 4.33 ± 0.69 4.47 ± 0.81 4.30 ± 0.66 0.057
Cretinine clearance rate [mL/min] 73.52 ± 38.62 57.22 ± 32.16 76.70 ± 39 0.000
Hemoglobin [g/dL] 12.84 ± 2.26 12.06 ± 2.43 12.99 ± 2.20 0.000
Total lymphocytes/mm3 1661.45± 1148.97 1583 ± 1125.79 1676.83 ± 1153.91 0.459
Signs and symptoms:
Crepitants 430 (71.67%) 79 (80.61%) 351 (69.92%) 0.032
Third heart sound 41 (6.83%) 9 (9.18%) 32 (6.37%) 0.313
Jugular ingurgitation 139 (23.17%) 22 (22.45%) 117 (23.31%) 0.854
Hepathomegalia 76 (12.67%) 14 (14.29%) 62 (12.35%) 0.598
Hepathojugular reflux 29 (4.83%) 5 (5.10%) 24 (4.78%) 0.892
Lower limb oedema 379 (63.16%) 72 (73.47%) 307 (61.16%) 0.021
Drug treatment:
ACE inhibitors 328 (54.67%) 41 (41.80%) 287 (57.20%) 0.005
Beta-blockers 188 (31.33%) 19 (19.40%) 169 (33.70%) 0.005
ARBs 104 (17.33%) 14 (14.30%) 90 (17.90%) 0.437
Calcium antagonists 951 (5.83%) 16 (16.30%) 79 (15.70%) 0.884
Antiagregants 263 (43.83%) 39 (39.80%) 224 (44.60%) 0.379
Oral anticoagulants 203 (33.83%) 23 (23.50%) 180 (35.90%) 0.018
Digoxine 152 (25.33%) 20 (20.40%) 132 (26.29%) 0.220
Diuretics 439 (73.17%) 69 (70.40%) 370 (73.70%) 0.500
Statins 150 (25.00%) 18 (18.36%) 132 (26.29%) 0.097
Isosorbide mononitrate 70 (11.67%) 14 (14.28%) 56 (11.15%) 0.373
*Echocardiogram available in 443 cases; Creatinine clearance rate estimated by MDRD equation; NYHA — New York Heart Association;
DPB — diastolic blood pressure; SBP — systolic blood pressure; ACE — angiotensin-converting enzyme; ARBs — angiotensin receptor blockers
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Clinical prediction rule table for risk
stratification. Table 4 shows an user-friendly table
for HF risk of death at 1 year stratification. It is com-
posed of 5 variables with entries for scoring with
adjusted weights.
Discussion
Our results confirm the prognostic value for HF
outcome of factors described previously such as age,
systolic dysfunction, creatinine clearance rate and
sodium levels, and provides strong evidence for new
prognostic factors as functional autonomy for daily
activities.
Age has an influence in the prognosis, thus in
patients under 50-year-old, the mortality rate was
4.9%, it was 12.3% for 50–75 years patients and
20.3% for those over 75. The risk of death after
1 year increased 3% for every year lived OR 1.03
(95% CI 1.003–1.067), and agrees with other stud-
ies [41]. The overall mortality observed in patients
Table 2. Basal non-biological characteristics of overall population study and comparison between
outcomes at 1 year after discharge in patients with heart failure.
Social characteristic All (n = 600) Death (n = 98) Non death (n = 502) P
Independent basic daily activities:
Yes 537 (89.50%) 72 (73.50%) 465 (92.60%) 0,000
No 63 (10.50%) 26 (26.50%) 37 (7.40%)
Independent instrumental activities:
Yes 521 (86.83%) 67 (68.40%) 454 (90.40%) 0,000
No 79 (13.17%) 31 (31.60%) 48 (9.60%)
Total dependent:
Yes 50 (8.33%) 21 (21.88%) 29 (5.75%) 0,000
No 550 (91.67%) 77 (78.60%) 473 (94.25%)
Social and family support:
Live alone 124 (20.67%) 20 (20.40%) 104 (20.71%) 0,951
Live with family 416 (69.33%) 69 (70.40%) 347 (69.12%)
Live in care center 60 (10.00%) 9 (9.18%) 51 (10.15%)
Table 3. Multivariate analysis predictor of mortality at 1 year in patients with heart failure (n = 600).
95% confidence interval
OR P Lower Upper
Age 1.03 0.028 1.003 1.067
Creatinine clearance rate at hospital admission [mL/min]* 0.988 0.043 0.97 0.99
Dependent basic daily activities 2.02 0.039 1.03 3.96
Pathophysiological diagnosis (systolic vs. diastolic) 2.67 0.004 1.36 5.23
Sodium 0.92 0.028 0.86 0.991
*Creatinine clearance estimated by MDRD equation; Statistic C: 0.763; R2 Negelkerke: 0.157; R2 Cox and Nell: 0.084; Correctly classified: 87%
0.00 0.25 0.50 0.75 1.00
1 – specificity











Figure 1. Receiver operating characteristic curve for
predictive 1-year mortality model for heart failure.
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with a history of ischemic cardiopathy, atrial fibril-
lation and valvulopathies was 19.4%, 15.2% and
20%, respectively. No significant differences were
found with alive patients group. These entities were
not associated with outcome. These findings dis-
agree with the results obtained by other studies
[18, 21, 22, 27, 33], but notice that patients could
be in a different stage of evolution.
Pathophysiologic diagnosis. It can also be
seen that systolic dysfunction is more frequent in
the group that dies (36.8% vs. 22.16%), so the prob-
ability of dying in the following year after diagnosis
is 2.67 times higher for the subjects with systolic
dysfunction (LVEF < 40%, OR 2.67, 95% CI 1.36–
–5.23; p = 0.004). It has been noted that the pres-
ence of ventricular dysfunction increases intrahos-
pital mortality [26] both at short term (30 days) [22]
and at long term (1 year) [20, 22, 27]. Although some
studies show that patients with systolic dysfunction
have a worse prognosis [26, 42, 43], others have not
found differences in survival between the patients
with or without ventricular dysfunction [40, 44, 45].
This discrepancies in the prognostic effect of LVEF
could be due again to different selection criteria or
disease stage of patients involved [44, 45]. It is
known that mortality increases for all causes when
LVEF decreases [20].
Kidney function: Creatinine clearance and
sodium levels. As in other studies [23, 46, 47], the
presence of kidney failure and hyponatremia were
associated with a worse prognosis. At 1 year after
the diagnosis of HF, those who die had a mean cre-
atinine clearance significantly lower: 57.2 ± 32.16
vs. 76.7 ± 39 mL/min. Additionally, in our study
creatinine clearance and sodium levels have been
demonstrated to be independent factors of good
prognosis, showing that for every unit increase of
these parameters the risk of mortality can be re-
duced by 2% (OR 0.988, 95% CI 0.97–0.99) and by
8% (OR 0.92, 95% CI 0.86–0.991), respectively.
Signs and symptoms at admission. The
presence of crepitants and lower limb edemas at the
moment of exploration in the first examination,
even high 80.6% vs. 73.4%, respectively, did not
change the prognosis. Surprisingly no sign or symp-
tom was identified as a negative prognosis factor,
such tachypnea, hypotension or tachycardia, seen
also in other studies [1, 15, 16], and including NYHA
functional class at admission. Although there is con-
troversies among studies [20].
Pharmacologic treatment. ACE inhibitors
and beta-blockers, as well as anticoagulants, were
proportionally less used in the group that died (42%
received ACE inhibitors and 19.7% received beta-
-blockers), but without prognostic value for outcome.
Independence for daily activities and
instrumental activities. The presence of depen-
dence for the basic daily activities was highly asso-
ciated with mortality (OR 2.02, 95% CI 1.03–3.96),
emerging as a potent and not mentioned indepen-
dent prognostic factor for HF. Worse basal condi-
tions could explain this fact, but in our study, the
presence of comorbidity does not correlate to the
degree of functional autonomy of patients. The de-
grees of dependence will mandatory drive the needs
for care in these patients.
Social and family support. However the
degree of social and familiar support was not asso-
ciated to the prognosis at 1 year in our study. Very
few studies included home living situation, social
support, and follow-up visits, among patients with
HF as a matter of study. Only it was found associa-
ted with readmissions [16, 34]. In acute myocardial
infarction, living alone has been described as
Table 4. Clinical prediction rule PREDICE-SCORE.
Score Probability
of death
Age [years] < 50 50–59 60–69 70–79 ≥ 80 0 < 10%
0 points 1 points 2 points 3 points 5 points 1–2 10–20%
Serum creatine clearance < 77 77–100 100–150 150–200 > 200 3–4 20–30%
(admission hospital) 9 points 7 points 6 points 4 points 0 points 5 30–40%
Dependent basic daily activities YES NO 6–7 40–55%
2 points 0 points 8–10 55–75%
Physiopathology diagnosis Systolic Diastolic 11–13 75–85%
(systolic vs. diastolic) 3 points 0 points 14–17 85–95%
Sodium < 135 135–145 > 145 18–22 > 95%
3 points 0 points 3 points
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a prognostic factor of mortality [33]. Different scales
for structural or functional measurement were used
in mentioned studies [48, 49]. Probably the inter-
view used in our study was not accurate enough and
an standardized approach would be needed for the
reliable measurement of these circumstances in the
clinical setting. The information provided by func-
tional and social assessment of patients profile has
a large potential for use in the planning of chronic
patient’s care turning traditional and expensive cli-
nical test to a more sustainable grounds.
Limitations of the study
The partial limitation of our study is that it is
a retrospective cohort analysis that represents first
results of a new predictive model. However, we
were able to develop a simple model PREDICE
SCORE to evaluate the 1-year risk for all cause
mortality from the combination of demographic
data, routine biochemistry and easy handling social
and functional variables at the point of care that al-
lows for risk stratification and therapeutical target-
ing. The variables included were non-invasive, un-
demanding to collect, and widely available, either
at emergencies room, hospitalization, discharge or
during outpatient visits (at point of care testing).
Personal functioning and social support are prog-
nostic factors which are usually ignored but which
have a great potential for action in individuals with
chronic diseases as HF in a sustainable way.
Clinical perspective
Congestive HF is a frequent and disabling con-
dition but with a modifiable course and a large po-
tential for improving. Many prognostic factors have
been described mainly based in clinical data, com-
plex heart, kidney and metabolic biochemical mark-
ers in addition to several image techniques.
Non biological factors as personal functioning
and social support are prognostic factors  usually
ignored, but with a great potential for information
for clinical action.
This study involved a cohort of 600 patients
from the first episode of HF, with the purpose to
determinate the predictive variables of 1-year mor-
tality and to develop a practical and user-friendly
clinical prediction algorithm (PREDICE-score) of
non-biological and biological factors for medical
decision about course of action.
In this study, creatinine clearance rate, levels
of sodium or presence of systolic dysfunction were
biological factors associate with prognosis of pa-
tients. We underline that being dependent for daily
basic activities was found as a relevant non-biolo-
gical prognostic factor. These findings are remark-
able, because these variables are non-invasive and
widely available. PREDICE-score is a predictive
tool, that lets and facilitates the risk stratification
for immediate care and help in decision-making
process, in a sustainable manner, and design of long-
-term strategies for secondary prevention in conges-
tive HF patients.
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